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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
The objectives are to assess the benefits and harms of combination of a beta-blocker plus a nitrate for prevention of variceal rebleeding.
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B A C K G R O U N D
Varices are present in 30% of patients with compensated and
60% of patients with decompensated cirrhosis (D’Amico 1997;
Tripathi 2001). Variceal bleeding occurs in one-third of these pa-
tients with mortality of 50% (Tripathi 2001). Patients with portal
hypertension who have bled from oesophageal varices have a very
high risk of variceal rebleeding. The risk of recurrence of haemor-
rhage from oesophageal varices is 60% to 70% at one year, if no
therapy for prevention of variceal rebleeding is instituted (Bernard
1997; Bernard-Chabert 2004). Factors determining the high risk
of recurrence of variceal hemorrhage are active bleeding on en-
doscopy, large esophageal varices, severity of index bleed, severity
of portal hypertension as determined by hepatic venous pressure
gradient (HVPG) measurement, hepatic decompensation, pres-
ence of encephalopathy, and renal impairment (Gluud 1988; de
Franchis 1992; Zaman 2005). Since there is high risk of recurrence
of variceal haemorrhage, patients with variceal bleeding should be
given effective therapy to prevent recurrence of variceal bleeding.
For prevention of recurrent variceal haemorrhage, drugs, endo-
scopic modes of treatment, surgery, or transjugular intrahepatic
portosystemic shunt are used (Zaman 2005). Drug therapy in por-
tal hypertension is administered to normalize the increased portal
blood inflow by using splanchnic vasoconstrictors like beta-block-
ers or to reduce intrahepatic vascular resistance by using isosor-
bide mononitrate. Beta-blockers (propranolol or nadolol) are the
most effective agents for preventionof variceal rebleeding (Tripathi
2001). Addition of isosorbide mononitrate increases the efficacy
of beta-blockers (Tripathi 2001). The therapeutic goals of drug
therapy are to attain reduction in HVPG to 20% of baseline value
or to 12 mm Hg to prevent or reduce the risk of rebleeding from
varices (Groszmann 1990; Feu 1995). Reduction in HVPG to 12
mm Hg or to 20% of baseline value are criteria used for labelling
responders. Patients not showing reduction in HVPG of this de-
gree are called nonresponders. With drug therapy, about 45% to
63% of patients are non-responders, and 46% to 65% of non-
responders have recurrence of variceal haemorrhage on drug ther-
apy compared to 7% to 13% of responders (Zaman 2005). It has
been found that haemodynamic response to drug therapy of portal
hypertension is usually sustained even after a long-term follow-up
(Villanueva 2004).
Combination drug therapy for prevention of rebleeding comprises
a vasoconstrictor (a beta-blocker: propranolol or nadolol) and a
nitrovasodilator (isosorbide mononitrate). The combination of a
beta-blocker and a nitrate leads to synergistic effect on reduction
of portal pressure. The combination of propranolol and isosorbide
mononitrate leads to greater reduction in portal pressure, better
haemodynamic control and more clinical benefits than achieved
with propranolol alone (Feu 1995; Villanueva 1996; Villanueva
2001;Tripathi 2001;Bureau 2002; Patch 2002; Zaman 2005). In
patients not responding to beta-blockers, isosorbide mononitrate
should be added. But this requires HVPG measurement before
adding isosorbide mononitrate. HVPG measurement should be
repeated within 1 to 2 weeks of starting treatment because the risk
of rebleeding is very high in the first six weeks after index bleed.
Other workers prefer to add isosorbide mononitrate to all the pa-
tients, thus avoiding repeat HVPG measurements. The studies
have shown that addition of isosorbide mononitrate to beta-block-
ers increase response rates in patients who do not show target re-
duction in HVPG with beta-blockers (Bureau 2002). About one-
third of non-responders to beta-blockers respond after addition of
isosorbide mononitrate.
Randomised trials and reviews have found combined drug ther-
apy to be effective for prevention of rebleeding from oesophageal
varices. However, the therapeutic effects in different trials are vari-
able, controversial and contradictory. The present Cochrane sys-
temic review will study the beneficial and harmful effects of com-
bined drug therapy for prevention of rebleeding from varices.
O B J E C T I V E S
The objectives are to assess the benefits and harms of combination
of a beta-blocker plus a nitrate for prevention of variceal rebleed-
ing.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include randomised clinical trials irrespective of blinding,
publication status, or language.
Types of participants
We will include patients with portal hypertension of any aetiology
having oesophageal varices with history of upper gastrointestinal
bleeding, that is likely to be variceal in origin.
Types of interventions
We will make the following comparisons:
- Combination of a beta-blocker plus a nitrate versus no interven-
tion
- Combination of a beta-blocker plus a nitrate versus placebo
- Combination of a beta-blocker plus a nitrate versus a beta-
blocker.
Other co-interventions will be allowed if used equally in the in-
terventions arms.
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Types of outcome measures
Primary outcome measure
(1) Rebleeding diagnosed by endoscopy or identification of hae-
matemesis, maelena, or gastric aspirate containing blood.
(2) All-cause mortality (at maximum follow-up).
Secondary outcome measures
(3) Rebleeding-related mortality.
(4) Adverse events. They will be defined as any untoward medical
occurrence not necessarily having a causal relationship with the
treatment, but resulting in a dose reduction or discontinuation of
the intervention (ICH-GCP 1997).
(5) Quality-of-life measures (as reported by authors).
Search methods for identification of studies
We will search for eligible trials in The Cochrane Hepato-Biliary
Group Controlled Trials Register, the Cochrane Central Register of
Controlled Trials in The Cochrane Library, MEDLINE, EMBASE,
and Science Citation Index Expanded (Royle 2003). The prelim-
inary search strategies are given in Appendix 1. Additional trials
will be identified through scanning of reference lists in relevant
papers and conference proceedings and correspondence with ex-
perts and pharmaceutical companies.
Data collection and analysis
One author (BCS) will develop the search strategies. Two authors
(BCS and SKS) will do the literature searches and extract data.
Disagreements will be resolved through discussion. LLG will serve
as adjudicator. Excluded trials will be listed with the reason for
exclusion. Primary authors of the included trials will be contacted
for additional information if outcome measures are not included
in the published trial reports.
Generation of allocation sequence, allocation concealment, blind-
ing, and follow-up will be extracted as measures of bias control (
Gluud 2001; Kjaergard 2001) using the following definitions:
Generation of the allocation sequence
• Adequate, if the allocation sequence was generated by a
computer or random number table. Drawing of lots, tossing of a
coin, shuffling of cards, or throwing dice will be considered as
adequate if a person who was not otherwise involved in the
recruitment of participants performed the procedure.
• Unclear, if the trial was described as randomised, but the
method used for the allocation sequence generation was not
described.
• Inadequate, if a system involving dates, names, or
admittance numbers were used for the allocation of patients.
These studies are known as quasi-randomised and will be
excluded from the review.
Allocation concealment
• Adequate, if the allocation of patients involved a central
independent unit, on-site locked computer, or sealed envelopes.
• Unclear, if the trial was described as randomised, but the
method used to conceal the allocation was not described.
• Inadequate, if the allocation sequence was known to the
investigators who assigned participants. Such studies will be
excluded.
Blinding
• Adequate, if blinded outcome assessment, data extraction,
or data analysis was reported. The nature of the interventions
assessed precludes adequate blinding of patients and health care
providers.
Follow-up
• Adequate, if the numbers and reasons for dropouts and
withdrawals in all intervention groups were described or if it was
specified that there were no dropouts or withdrawals.
• Unclear, if the report gave the impression that there had
been no dropouts or withdrawals, but this was not specifically
stated.
• Inadequate, if the number or reasons for dropouts and
withdrawals were not described.
The number and reasons for losses to follow-up will be extracted
to assess the risk of attrition bias.
From the individual trials we will also extract data on the baseline
characteristics of patients (inclusions criteria, mean age, sex, and
number of patients with alcoholic liver disease), treatments (type
and dose of therapy), and trials (country of origin, publication
status, funding, duration of follow up, and all outcomes).
Further, we will extract information on whether sample-size and
intention-to-treat analysis were performed in the trials.
Statistical analyses
The analyses will be performed in RevMan (RevMan 2003) and
STATA version 8.0 for Windows. Results of meta-analyses will
be presented as relative risks (RR) with 95% confidence inter-
vals (95% CI). Random-effects models will be used in the pri-
mary analyses because of the expected clinical heterogeneity. Chi-
squared analyses will be performed to estimate inter-trial hetero-
geneity. All analyses will be performed using the intention-to-treat
principle including all randomised patients irrespective of compli-
ance or follow-up. For patients with missing data, carry forward of
the last observed response will be used. Worst-case scenario anal-
yses in which patients with missing data will be counted as treat-
ment failures will be performed to assess the risk of attrition bias.
Random-effects meta-regression analyses will be performed to as-
sess the potential sources of heterogeneity. Fixed-effect meta-anal-
yses will be performed in which trials will be grouped according
to significant predictors of heterogeneity identified in the meta-
regression analyses. The risk of bias will be evaluated in regression
analyses of funnel plot asymmetry and in subgroup meta-analyses
3Beta-blocker plus nitrates for secondary prevention of variceal bleeding (Protocol)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
with trials stratified by publication status and allocation conceal-
ment. The outcome measure in the regression and subgroup anal-
yses will be rebleeding and mortality.
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A P P E N D I C E S
Appendix 1. Search Strategies
Database Date of search Search terms Number of hits
The Cochrane Hepatobiliary
Group Controlled Trials Regis-
ter
(beta-blocker* OR ’adrenergic beta an-
tagonist*’ OR propranolol OR atenolol
OR nadolol OR metoprolol OR biso-
prolol OR carvedilol OR tertatolol OR
nipradilol OR penbutolol OR tim-
olol OR mepindolol OR ’isosorbid*
mononitrat*’ OR imdur OR ismo OR
monoket) AND ’*esophageal varic*’
OR variceal rebleeding OR secondary
prophylaxis for variceal bleeding
The Cochrane Library (Issue 2,
2006)
#1 MeSH descriptor Adrenergic beta-
Antagonists explode all trees in MeSH
products 8076
#2 MeSH descriptor Propranolol ex-
plode all trees in MeSH products 2376
#3 MeSH descriptor Atenolol explode
all trees in MeSH products 1464
#4 MeSH descriptor Nadolol explode
all trees in MeSH products 153
#5 MeSH descriptor Metoprolol ex-
plode all trees in MeSH products 1183
#6MeSHdescriptor Bisoprolol explode
all trees in MeSH products 183
#7 MeSH descriptor Penbutolol ex-
plode all trees in MeSH products 51
#8 MeSH descriptor Timolol explode
all trees in MeSH products 720
#9 beta-blocker* or adrenergic beta an-
tagonist* or propranolol or atenolol or
nadolol or metoprolol or bisoprolol or
carvedilol or tertatolol or nipradilol or
penbutolol or timolol or mepindolol in
All Fields in all products 10724
#10 isosorbid* mononitrat* or imdur
or ismo or monoket in All Fields in all
products 217
#11 (#1 OR #2 OR #3 OR #4 OR #5
OR #6 OR #7 OR #8 OR #9 OR #10)
12599
#12 MeSH descriptor Esophageal and
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(Continued)
Gastric Varices explode all trees in
MeSH products 641
#13 *esophageal varic* in All Fields in
all products 1099
#14 (#12 OR #13) 1099
#15 (#11 AND #14) 226
MEDLINE #127853explode “Adrenergic-beta-An-
tagonists”/all subheadings
#228459explode “Propranolol”/all
subheadings
#33938explode “Atenolol”/all
subheadings
#4662explode “Nadolol”/all subhead-
ings
#53712explode “Metoprolol”/all sub-
headings
#6534explode “Bisoprolol”/all sub-
headings
#7173explode “Penbutolol”/all sub-
headings
#82593explode “Timolol”/all subhead-
ings
#9 71892beta-blocker* or adrenergic
beta antagonist* or propranolol or
atenolol or nadolol or metoprolol or
bisoprolol or carvedilol or tertatolol or
nipradilol or penbutolol or timolol or
mepindolol
#10834isosorbid* mononitrat* or im-
dur or ismo or monoket
#1172593#1 or #2 or #3 or #4 or #5 or
#6 or #7 or #8 or #9 or #10
#129288explode “Esophageal-and-
Gastric-Varices”/all subheadings
#1310983(oesophageal or esophageal)
and varic*
#1410983#12 or #13
#15592#11 and #14
#16536388random* or blind* or
placebo* or meta-analysis
#17210#15 and #16
EMBASE #1125183explode “beta-adrenergic-re-
ceptor-blocking-agent”/all
subheadings
#252448explode “propranolol”/all sub-
headings
#316176explode “atenolol”/all sub-
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(Continued)
headings
#43420explode “nadolol”/all subhead-
ings
#515176explode “metoprolol”/all sub-
headings
#62659explode “bisoprolol”/all sub-
headings
#73995explode “carvedilol”/all sub-
headings
#8283explode “tertatolol”/all subhead-
ings
#9280explode “nipradilol”/all
subheadings
#10680explode “penbutolol”/all sub-
headings
#116887explode “timolol”/all
subheadings
#12207explode “mepindolol”/all sub-
headings
#1386717beta-blocker* or adrenergic
beta antagonist* or propranolol or
atenolol or nadolol or metoprolol or
bisoprolol or carvedilol or tertatolol or
nipradilol or penbutolol or timolol or
mepindolol
#141548isosorbid* mononitrat* or im-
dur or ismo or monoket
#15129630#1 or #2 or #3 or #4 or #5
or #6 or #7 or #8 or #9 or #10 or #11
or #12 or #13 or #14
#166445explode “esophagus-varices”/
all subheadings
#174791(oesophageal or esophageal)
and varic*
#187440#16 or #17
#19994#15 and #18
#20469358random* or blind* or
placebo* or meta-analysis
#21288#19 and #20
Science Citation Index Ex-
panded
#7 289 #6 AND #5
#6 >100,000 TS=(random* or blind*
or placebo* or meta-analysis)
#5 491 #4 AND #3
#4 5,557 TS=((oesophageal or
esophageal)and varic*)
#3 41,346 #2 OR #1
#2 349 TS=(isosorbid* mononitrat* or
imdur or ismo or monoket)
7Beta-blocker plus nitrates for secondary prevention of variceal bleeding (Protocol)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
#1 41,109 TS=(beta-blocker* or adren-
ergic beta antagonist* or propranolol
or atenolol or nadolol or metoprolol or
bisoprolol or carvedilol or tertatolol or
nipradilol or penbutolol or timolol or
mepindolol)
WH A T ’ S N E W
21 October 2008 Amended Converted to new RevMan 5 format
H I S T O R Y
Protocol first published: Issue 3, 2007
C O N T R I B U T I O N S O F A U T H O R S
BCS wrote the protocol. SKS approved the contents of the protocol.
D E C L A R A T I O N S O F I N T E R E S T
None known.
S O U R C E S O F S U P P O R T
Internal sources
• No sources of support supplied
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External sources
• Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen University Hospital, Rigshospitalet, Denmark.
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